Clinical Trial Results:
Efficacy and safety of FIAsp in a basal-bolus regimen versus basal insulin therapy, both in combination with metformin in adult Subjects with type 2 diabetes
Due to the EudraCT – Results system being out of service between 31 July 2015 and 12 January 2016, these results have been published in compliance with revised timelines.
Summary
|
|
EudraCT number |
2012-005583-10 |
Trial protocol |
SI |
Global end of trial date |
17 Nov 2014
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
27 Jul 2016
|
First version publication date |
27 Jul 2016
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
NN1218-4049
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT01850615 | ||
WHO universal trial number (UTN) |
U1111-1137-6242 | ||
Sponsors
|
|||
Sponsor organisation name |
Novo Nordisk A/S
|
||
Sponsor organisation address |
Novo Allé, Bagsvaerd, Denmark, 2880
|
||
Public contact |
Global Clinical Registry (GCR, 1452), Novo Nordisk A/S, clinicaltrials@novonordisk.com
|
||
Scientific contact |
Global Clinical Registry (GCR, 1452), Novo Nordisk A/S, clinicaltrials@novonordisk.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
09 Jul 2015
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
17 Nov 2014
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
17 Nov 2014
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To confirm superiority of meal-time faster-acting insulin aspart (FIAsp)/faster aspart in a full basal-bolus regimen versus basal insulin therapy, both in combination with metformin, in terms of glycaemic control after 18-weeks of randomised treatment.
|
||
Protection of trial subjects |
The trial was conducted in accordance with the Declaration of Helsinki and ICH Good Clinical Practice and 21 CFR 312.120
|
||
Background therapy |
Metformin (≥1000 mg) was used as background therapy. At the start of the 8-week run-in (pre-assignment) period, subjects continued on the once daily (OD) basal insulin (insulin detemir or insulin glargine or Neutral Protamine Hagedorn (NPH) insulin) and metformin at the same dose level as before the trial. Subjects were instructed to discontinue all other OADs at the start of the run in period (visit 2). During the run-in period, basal insulin dose was adjusted weekly. | ||
Evidence for comparator |
Not applicable | ||
Actual start date of recruitment |
23 Sep 2013
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Argentina: 44
|
||
Country: Number of subjects enrolled |
India: 61
|
||
Country: Number of subjects enrolled |
Mexico: 31
|
||
Country: Number of subjects enrolled |
Romania: 28
|
||
Country: Number of subjects enrolled |
Slovenia: 32
|
||
Country: Number of subjects enrolled |
United States: 40
|
||
Worldwide total number of subjects |
236
|
||
EEA total number of subjects |
60
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
177
|
||
From 65 to 84 years |
59
|
||
85 years and over |
0
|
|
|||||||||||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||||||||||
Recruitment details |
The trial was conducted at 51 sites in 6 countries as follows: Argentina: 4 sites; India: 8 sites; Mexico: 3 sites; Romania: 5 sites; Slovenia: 4 sites; United States: 27 sites. | ||||||||||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||||||||||
Screening details |
Included subjects were with type 2 diabetes mellitus, who were being treated with once daily (OD) insulin detemir or insulin glargine or NPH insulin, in addition to metformin (≥1000 mg) ± other OADs. A total of 555 subjects were screened, of which 232 subjects were screening failures and 323 subjects entered the run-in (pre-assignment) period. | ||||||||||||||||||||||||||||||
Pre-assignment period milestones
|
|||||||||||||||||||||||||||||||
Number of subjects started |
323 [1] | ||||||||||||||||||||||||||||||
Number of subjects completed |
236 | ||||||||||||||||||||||||||||||
Pre-assignment subject non-completion reasons
|
|||||||||||||||||||||||||||||||
Reason: Number of subjects |
Failure to meet randomization criteria: 62 | ||||||||||||||||||||||||||||||
Reason: Number of subjects |
Adverse event, non-fatal: 1 | ||||||||||||||||||||||||||||||
Reason: Number of subjects |
Protocol deviation: 12 | ||||||||||||||||||||||||||||||
Reason: Number of subjects |
Lack of efficacy: 1 | ||||||||||||||||||||||||||||||
Reason: Number of subjects |
Lost to follow-up: 1 | ||||||||||||||||||||||||||||||
Reason: Number of subjects |
Consent withdrawn by subject: 8 | ||||||||||||||||||||||||||||||
Reason: Number of subjects |
Unclassified: 2 | ||||||||||||||||||||||||||||||
Notes [1] - The number of subjects reported to have started the pre-assignment period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same. Justification: A total of 323 subjects entered the run-in (pre-assignment) period of the trial; of which, 87 subjects were run-in failures. Hence, 236 subjects were enrolled to the 18 weeks of treatment period. |
|||||||||||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||||||||||
Period 1 title |
Overall Study (overall period)
|
||||||||||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||||||||||||||
Blinding implementation details |
Not applicable
|
||||||||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||||||||
Arm title
|
Faster aspart + Basal | ||||||||||||||||||||||||||||||
Arm description |
During the 18-week treatment period, subjects received subcutaneous (s.c., under the skin) injection of faster aspart (bolus insulin) along with s.c. basal insulin (insulin detemir or insulin glargine or NPH insulin) and metformin. Treatment recommendations were developed for the different trial products specifying the recommended dose adjustments at different plasma glucose (PG) levels. Trial products were titrated according to the insulin dosing recommendations provided during the study. No maximum dose of insulin was specified as doses were titrated individually. | ||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||
Investigational medicinal product name |
Faster aspart
|
||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||
Pharmaceutical forms |
Solution for injection
|
||||||||||||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||||||||||||||||||||
Dosage and administration details |
Faster aspart was used for bolus insulin administration at each main meal (i.e., breakfast, lunch and main evening meal) and was to be injected subcutaneously into the abdomen. Injection sites were to be rotated within the same area. The bolus insulin injection was to be given 0–2 minutes before each main meal.
|
||||||||||||||||||||||||||||||
Investigational medicinal product name |
Insulin detemir
|
||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||
Other name |
Levemir®
|
||||||||||||||||||||||||||||||
Pharmaceutical forms |
Solution for injection
|
||||||||||||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||||||||||||||||||||
Dosage and administration details |
Insulin detemir was used for basal insulin administration and was to be injected subcutaneously into the thigh or upper arm (deltoid area). The basal insulin injection was to be given OD, in the evening, at approximately the same time each day. Changing the frequency (e.g., from OD to twice daily [BID]) of basal insulin dosing during the trial was not allowed.
|
||||||||||||||||||||||||||||||
Investigational medicinal product name |
NPH insulin
|
||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||
Other name |
Insulatard®, Protaphane®, Novolin N™
|
||||||||||||||||||||||||||||||
Pharmaceutical forms |
Suspension for injection
|
||||||||||||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||||||||||||||||||||
Dosage and administration details |
NPH insulin was used for basal insulin administration and was to be injected subcutaneously into the thigh or upper arm (deltoid area). The basal insulin injection was to be given OD, in the evening, at approximately the same time each day. Changing the frequency (e.g., from OD to BID) of basal insulin dosing during the trial was not allowed.
|
||||||||||||||||||||||||||||||
Investigational medicinal product name |
Insulin glargine
|
||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||
Other name |
Lantus®
|
||||||||||||||||||||||||||||||
Pharmaceutical forms |
Solution for injection
|
||||||||||||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||||||||||||||||||||
Dosage and administration details |
Insulin glargine was used for basal insulin administration and was to be injected subcutaneously into the thigh or upper arm (deltoid area). The basal insulin injection was to be given OD, in the evening, at approximately the same time each day. Changing the frequency (e.g., from OD to BID) of basal insulin dosing during the trial was not allowed.
|
||||||||||||||||||||||||||||||
Arm title
|
Basal | ||||||||||||||||||||||||||||||
Arm description |
During the 18-week treatment period, subjects received s.c. injection of basal insulin (insulin detemir or insulin glargine or NPH insulin) and metformin. Treatment recommendations were developed for the different trial products specifying the recommended dose adjustments at different plasma glucose (PG) levels. Trial products were titrated according to the insulin dosing recommendations provided during the study. No maximum dose of insulin was specified as doses were titrated individually. | ||||||||||||||||||||||||||||||
Arm type |
Active comparator | ||||||||||||||||||||||||||||||
Investigational medicinal product name |
Insulin detemir
|
||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||
Other name |
Levemir®
|
||||||||||||||||||||||||||||||
Pharmaceutical forms |
Solution for injection
|
||||||||||||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||||||||||||||||||||
Dosage and administration details |
Insulin detemir was used for basal insulin administration and was to be injected subcutaneously into the thigh or upper arm (deltoid area). The basal insulin injection was to be given OD, in the evening, at approximately the same time each day. Changing the frequency (e.g., from OD to BID) of basal insulin dosing during the trial was not allowed.
|
||||||||||||||||||||||||||||||
Investigational medicinal product name |
NPH insulin
|
||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||
Other name |
Insulatard®, Protaphane®, Novolin N™
|
||||||||||||||||||||||||||||||
Pharmaceutical forms |
Suspension for injection
|
||||||||||||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||||||||||||||||||||
Dosage and administration details |
NPH insulin was used for basal insulin administration and was to be injected subcutaneously into the thigh or upper arm (deltoid area). The basal insulin injection was to be given OD, in the evening, at approximately the same time each day. Changing the frequency (e.g., from OD to BID) of basal insulin dosing during the trial was not allowed.
|
||||||||||||||||||||||||||||||
Investigational medicinal product name |
Insulin glargine
|
||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||
Other name |
Lantus®
|
||||||||||||||||||||||||||||||
Pharmaceutical forms |
Solution for injection
|
||||||||||||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||||||||||||||||||||
Dosage and administration details |
Insulin glargine was used for basal insulin administration and was to be injected subcutaneously into the thigh or upper arm (deltoid area). The basal insulin injection was to be given OD, in the evening, at approximately the same time each day. Changing the frequency (e.g., from OD to BID) of basal insulin dosing during the trial was not allowed.
|
||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Faster aspart + Basal
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
During the 18-week treatment period, subjects received subcutaneous (s.c., under the skin) injection of faster aspart (bolus insulin) along with s.c. basal insulin (insulin detemir or insulin glargine or NPH insulin) and metformin. Treatment recommendations were developed for the different trial products specifying the recommended dose adjustments at different plasma glucose (PG) levels. Trial products were titrated according to the insulin dosing recommendations provided during the study. No maximum dose of insulin was specified as doses were titrated individually. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Basal
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
During the 18-week treatment period, subjects received s.c. injection of basal insulin (insulin detemir or insulin glargine or NPH insulin) and metformin. Treatment recommendations were developed for the different trial products specifying the recommended dose adjustments at different plasma glucose (PG) levels. Trial products were titrated according to the insulin dosing recommendations provided during the study. No maximum dose of insulin was specified as doses were titrated individually. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Faster aspart + Basal
|
||
Reporting group description |
During the 18-week treatment period, subjects received subcutaneous (s.c., under the skin) injection of faster aspart (bolus insulin) along with s.c. basal insulin (insulin detemir or insulin glargine or NPH insulin) and metformin. Treatment recommendations were developed for the different trial products specifying the recommended dose adjustments at different plasma glucose (PG) levels. Trial products were titrated according to the insulin dosing recommendations provided during the study. No maximum dose of insulin was specified as doses were titrated individually. | ||
Reporting group title |
Basal
|
||
Reporting group description |
During the 18-week treatment period, subjects received s.c. injection of basal insulin (insulin detemir or insulin glargine or NPH insulin) and metformin. Treatment recommendations were developed for the different trial products specifying the recommended dose adjustments at different plasma glucose (PG) levels. Trial products were titrated according to the insulin dosing recommendations provided during the study. No maximum dose of insulin was specified as doses were titrated individually. |
|
|||||||||||||||||||
End point title |
Change from baseline in HbA1c | ||||||||||||||||||
End point description |
For this endpoint, baseline (week 0) and week 18 have been presented, where week 18 data are the “end of trial” data containing last available measurements. Analysis population: Full analysis set (FAS); the FAS included all randomised subjects. n = treatment wise number of subjects analysed for individual time-point.
|
||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||
End point timeframe |
After 18 weeks of randomised treatment
|
||||||||||||||||||
|
|||||||||||||||||||
Statistical analysis title |
"Faster aspart + Basal" versus "Basal" | ||||||||||||||||||
Statistical analysis description |
Change from baseline in HbA1c after 18 weeks of treatment was analysed using a mixed-effect model for repeated measurements (MMRM) where all calculated changes in HbA1c from baseline at visits 16, 22 and 28 were included in the analysis. This model included treatment, region and strata as fixed factors, subject as random effect, baseline HbA1c as covariate and interaction between all fixed effects and visit, and between the covariate and visit.
|
||||||||||||||||||
Comparison groups |
Faster aspart + Basal v Basal
|
||||||||||||||||||
Number of subjects included in analysis |
236
|
||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||
Analysis type |
superiority [1] | ||||||||||||||||||
Method |
|||||||||||||||||||
Parameter type |
Treatment difference | ||||||||||||||||||
Point estimate |
-0.94
|
||||||||||||||||||
Confidence interval |
|||||||||||||||||||
level |
95% | ||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||
lower limit |
-1.17 | ||||||||||||||||||
upper limit |
-0.72 | ||||||||||||||||||
Notes [1] - Superiority was considered confirmed if the upper bound of the two-sided 95% confidence interval (CI) for the estimated treatment difference (faster aspart+basal minus basal only), which was calculated using the FAS, was below 0%. |
|
||||||||||||||||||||||
End point title |
Self-measured plasma glucose (SMPG) 7- point profile: Post prandial plasma glucose (PPG), overall 2-hour mean (of breakfast, lunch, main evening meal) | |||||||||||||||||||||
End point description |
For this endpoint the "end of trial" data containing last available measurements are presented. PPG measurements were recorded by the subjects at 2 hours after each meal (breakfast, lunch and main evening meal) as part of three 7-point profiles (SMPG) prior to the visits. Individual mean meal PPG (post-breakfast, post-lunch, post-main evening meal) was derived from the three measurements. Overall mean PPG was derived from the individual derived meal time mean PPG values. Analysis population: FAS; the FAS included all randomised subjects. n = treatment wise number of subjects analysed for individual time-point.
|
|||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||
End point timeframe |
After 18 weeks of randomised treatment
|
|||||||||||||||||||||
|
||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||
End point title |
Self-measured plasma glucose (SMPG) 7- point profile: Prandial plasma glucose (PG) increment, overall 2-hour mean (of breakfast, lunch, main evening meal) | |||||||||||||||||||||
End point description |
For this endpoint the "end of trial" data containing last available measurements are presented. Prandial PG increment for each meal (breakfast, lunch, main evening meal) was derived from the 7-point profiles (SMPG) as the difference between the PPG value 2 hours after each meal and the PG value before each meal. Individual mean meal PPG (post-breakfast, post-lunch, post-main evening meal) was derived from the three measurements. Overall mean PPG was derived from the individual derived meal time mean PPG values. Analysis population: FAS; the FAS included all randomised subjects. n = treatment wise number of subjects analysed for individual time-point.
|
|||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||
End point timeframe |
After 18 weeks of randomised treatment
|
|||||||||||||||||||||
|
||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change from baseline in body weight | ||||||||||||||||||
End point description |
For this endpoint, baseline (week 0) and week 18 have been presented, where week 18 data are the “end of trial” data containing last available measurements. Analysis population: FAS; the FAS included all randomised subjects. n = treatment wise number of subjects analysed for individual time-point.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
After 18 weeks of randomised treatment
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Number of treatment emergent hypoglycaemic episodes | |||||||||
End point description |
Plasma glucose (PG) was always to be measured and recorded when a hypoglycaemic episode was suspected. All PG values ≤3.9 mmol/L (70 mg/dL) or >3.9 mmol/L (70 mg/dL) when they occurred in conjunction with hypoglycaemic symptoms were to be recorded by the subject. Numbers of treatment emergent hypoglycaemic episodes were recorded during 18 weeks of treatment. Analysis population: Safety Analysis Set (SAS); the SAS included all subjects receiving at least one dose of the investigational product or its comparator.
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
During 18 weeks of randomised treatment
|
|||||||||
|
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Number of adverse events | |||||||||
End point description |
All adverse events (AEs) described here refer to treatment emergent adverse events (TEAE). A TEAE was defined as an event that had onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment, week 18. Analysis population: SAS; the SAS included all subjects receiving at least one dose of the investigational product or its comparator.
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
During 18 weeks of randomised treatment period.
|
|||||||||
|
||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
During 18 weeks of randomised treatment period + 7 days of follow-up period.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
All AEs described here refer to TEAE. Analysis population: SAS - included all subjects receiving at least one dose of the investigational product or its comparator. Number of deaths causally related to treatment is the data considered to present under "total number of deaths resulting from adverse events".
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
17
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Faster aspart + Basal
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
During the 18-week treatment period, subjects received subcutaneous (s.c., under the skin) injection of faster aspart (bolus insulin) along with s.c. basal insulin (insulin detemir or insulin glargine or NPH insulin) and metformin. Treatment recommendations were developed for the different trial products specifying the recommended dose adjustments at different plasma glucose (PG) levels. Trial products were titrated according to the insulin dosing recommendations provided during the study. No maximum dose of insulin was specified as doses were titrated individually. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Basal
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
During the 18-week treatment period, subjects received s.c. injection of basal insulin (insulin detemir or insulin glargine or NPH insulin) and metformin. Treatment recommendations were developed for the different trial products specifying the recommended dose adjustments at different plasma glucose (PG) levels. Trial products were titrated according to the insulin dosing recommendations provided during the study. No maximum dose of insulin was specified as doses were titrated individually. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
26 Aug 2013 |
1) Addition of a 30-day follow-up period to collect major adverse cardiovascular event (MACE) information.
2) Collection of smoking history and post-trial diabetes treatment.
3) Statement added to specify that subjects without post-randomisation HbA1c data were not to be included in analysis of the primary endpoint.
4) Section added on handling of missing data.
5) Update of hypoglycaemia classification and adverse event outcome definitions.
6) Correction of minor inconsistencies.
|
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |